Last reviewed · How we verify
Combined metabolic activators
Combined metabolic activators enhance cellular energy production and metabolic efficiency by simultaneously activating multiple metabolic pathways.
At a glance
| Generic name | Combined metabolic activators |
|---|---|
| Sponsor | ScandiBio Therapeutics AB |
| Modality | Small molecule |
| Therapeutic area | Metabolic Disease |
| Phase | Phase 3 |
Mechanism of action
This drug class works by targeting and activating key metabolic regulators and energy-producing pathways within cells, potentially including mitochondrial function enhancers and metabolic enzyme activators. By coordinating activation across multiple metabolic nodes, the therapy aims to improve cellular energy status and metabolic homeostasis, which may benefit conditions characterized by metabolic dysfunction or energy deficit.
Approved indications
Common side effects
Key clinical trials
- Combined Metabolic Activator Supplementation in Subjects Diagnosed With Alzheimer's Disease (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Combined metabolic activators CI brief — competitive landscape report
- Combined metabolic activators updates RSS · CI watch RSS
- ScandiBio Therapeutics AB portfolio CI